Literature DB >> 23076074

Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia.

Patrick Gavin Kehoe1, Neil Martin Davies, Richard Michael Martin, Yoav Ben-Shlomo.   

Abstract

We investigated whether angiotensin II receptor blockers and angiotensin converting enzyme inhibitors were associated with risk of mortality or inpatient hospitalization for patients with dementia compared to other antihypertensive medications. We extracted a clinical cohort of 6,290 patients with dementia from the United Kingdom General Practice Research Database, prescribed antihypertensive medication at diagnosis of dementia with around 10 years follow-up. Using survival analysis we estimated associations of exposure to antihypertensive medication with subsequent hospitalization and mortality risk, stratified by dementia type (Alzheimer's disease, vascular and other dementias). Angiotensin converting enzyme inhibitors (but not angiotensin II receptor blockers) were associated with an increased risk of mortality in patients with Alzheimer's disease (adjusted hazard ratio: 1.19; 95% CI 1.07, 1.33, p = 0.002), but no convincing evidence of increased hospitalization. Angiotensin II receptor blockers were inversely associated with hospitalization for any form of dementia, but after adjustment for covariates, these associations became consistent with chance. Further evidence is required to either support or refute the observation that exposure to angiotensin converting enzyme inhibitors in patients with dementia is associated with increased mortality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23076074     DOI: 10.3233/JAD-2012-121090

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  12 in total

Review 1.  Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.

Authors:  Romain Barus; Johana Béné; Julie Deguil; Sophie Gautier; Régis Bordet
Journal:  Br J Pharmacol       Date:  2019-03-31       Impact factor: 8.739

2.  Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease.

Authors:  Maya Koronyo-Hamaoui; Julia Sheyn; Eric Y Hayden; Songlin Li; Dieu-Trang Fuchs; Giovanna C Regis; Dahabada H J Lopes; Keith L Black; Kenneth E Bernstein; David B Teplow; Sebastien Fuchs; Yosef Koronyo; Altan Rentsendorj
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

3.  Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia.

Authors:  Yang Gao; Rónán O'Caoimh; Liam Healy; David M Kerins; Joseph Eustace; Gordon Guyatt; David Sammon; D William Molloy
Journal:  BMJ Open       Date:  2013-07-25       Impact factor: 2.692

4.  The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease.

Authors:  Hadassa M Jochemsen; Charlotte E Teunissen; Emma L Ashby; Wiesje M van der Flier; Ruth E Jones; Mirjam I Geerlings; Philip Scheltens; Patrick G Kehoe; Majon Muller
Journal:  Alzheimers Res Ther       Date:  2014-05-15       Impact factor: 6.982

Review 5.  Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review.

Authors:  Raffaella Valenti; Leonardo Pantoni; Hugh S Markus
Journal:  BMC Med       Date:  2014-11-11       Impact factor: 8.775

Review 6.  The Coming of Age of the Angiotensin Hypothesis in Alzheimer's Disease: Progress Toward Disease Prevention and Treatment?

Authors:  Patrick Gavin Kehoe
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer's disease.

Authors:  Karim Fazal; Gayan Perera; Mizanur Khondoker; Robert Howard; Robert Stewart
Journal:  BJPsych Open       Date:  2017-07-04

Review 8.  Dementia ascertainment using existing data in UK longitudinal and cohort studies: a systematic review of methodology.

Authors:  Ruth A Sibbett; Tom C Russ; Ian J Deary; John M Starr
Journal:  BMC Psychiatry       Date:  2017-07-03       Impact factor: 3.630

9.  Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease.

Authors:  Ziheng Hu; Lirong Wang; Shifan Ma; Levent Kirisci; Zhiwei Feng; Ying Xue; William E Klunk; M Ilyas Kamboh; Robert A Sweet; James Becker; Qianzhou Lv; Oscar L Lopez; Xiang-Qun Xie
Journal:  Alzheimers Dement (N Y)       Date:  2018-10-14

Review 10.  Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.

Authors:  J Scott Miners; Jennifer C Palmer; Hannah Tayler; Laura E Palmer; Emma Ashby; Patrick G Kehoe; Seth Love
Journal:  Front Aging Neurosci       Date:  2014-09-11       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.